1. Home
  2. FA vs NRIX Comparison

FA vs NRIX Comparison

Compare FA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Advantage Corporation

FA

First Advantage Corporation

HOLD

Current Price

$20.19

Market Cap

3.1B

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$23.59

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FA
NRIX
Founded
2003
2009
Country
United States
United States
Employees
N/A
357
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FA
NRIX
Price
$20.19
$23.59
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
$15.67
$30.50
AVG Volume (30 Days)
2.1M
3.2M
Earning Date
05-07-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
72.97
N/A
EPS
0.01
N/A
Revenue
$1,574,389,000.00
$76,987,000.00
Revenue This Year
$8.42
N/A
Revenue Next Year
$7.26
$48.05
P/E Ratio
$2,053.00
N/A
Revenue Growth
83.02
99.31
52 Week Low
$8.82
$8.20
52 Week High
$20.59
$24.88

Technical Indicators

Market Signals
Indicator
FA
NRIX
Relative Strength Index (RSI) 80.15 81.30
Support Level $14.07 $14.63
Resistance Level N/A N/A
Average True Range (ATR) 0.85 1.35
MACD 0.30 0.69
Stochastic Oscillator 98.81 89.14

Price Performance

Historical Comparison
FA
NRIX

About FA First Advantage Corporation

First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: